A Study of SGN-STNV in Advanced Solid Tumors
Conditions: Non-small Cell Lung Cancer (NSCLC); Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Gastric Cancer and Gastroesophageal Junction (GEJ) Carcinoma; Colorectal Cancer; Exocrine Pancreatic Adenocarcinoma; Appendiceal Adenocarcinoma; Pseudomyxoma Peritonei
Intervention: Drug: SGN-STNV
Sponsor: Seagen Inc.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.